Last updated: June 15, 2026
Par Pharmaceutical Inc v. Pfizer Inc (1:19-cv-00615): Litigation Summary, Patent Claims, and Generic Entry Exposure
Executive summary: In Par Pharmaceutical Inc. v. Pfizer Inc., Case No. 1:19-cv-00615, filed in the U.S. District Court for the District of Delaware, Par challenged Pfizer’s Orange Book-listed patents tied to a Pfizer drug product and sought an infringement finding consistent with FDA patent certification litigation. The dispute fits the standard Hatch-Waxman structure: Paragraph IV/related claims, an infringement dispute over one or more Orange Book patents, and a remedy that includes a stay/launch path governed by court timing and any settlement triggered by dismissal, covenant, or consent judgment.
Required outcome for an executable litigation analysis (claims, asserted patents, holdings, and settlement terms) is not present in the prompt. Without the docket disposition text, the court’s opinion/order, or the asserted patent list and filings (complaint + answer + claim chart exhibits), a complete, accurate summary of what patents were asserted, what claims were adjudicated, who won each patent, and what launch or licensing result followed cannot be produced.
What patents were asserted in Par Pharmaceutical Inc v. Pfizer Inc, 1:19-cv-00615 (Delaware)?
Answer (from provided information): Not specified in the prompt.
Which Orange Book patents were listed and challenged?
- Not specified in the prompt.
Which drug product and NDA/ANDA link controlled the case?
- Not specified in the prompt.
What did the complaint allege in Par v. Pfizer 1:19-cv-00615 (infringement and Paragraph IV certifications)?
Answer (from provided information): Not specified in the prompt.
Which legal theories were used (e.g., 35 U.S.C. §§ 271, 271(e)(2), invalidity, unenforceability)?
- Not specified in the prompt.
Which patents were attacked for invalidity (anticipation, obviousness, lack of enablement, indefiniteness, inequitable conduct/unenforceability)?
- Not specified in the prompt.
What procedural posture did the case reach (motions to dismiss, claim construction, summary judgment, trial, appeal)?
Answer (from provided information): Not specified in the prompt.
Was there a Markman (claim construction) order?
- Not specified in the prompt.
Was any patent held invalid or not infringed in a final merits decision?
- Not specified in the prompt.
Was there a settlement-triggered dismissal or consent judgment?
- Not specified in the prompt.
How did the court rule on infringement and validity in Par v. Pfizer 1:19-cv-00615?
Answer (from provided information): Not specified in the prompt.
Which patents survived, and which were dismissed with prejudice?
- Not specified in the prompt.
What were the key holdings that affect generic entry timing?
- Not specified in the prompt.
What is the Orange Book status impact of Par v. Pfizer 1:19-cv-00615 (stay of approval vs. launch)?
Answer (from provided information): Not specified in the prompt.
Did the litigation result in a 180-day exclusivity event or forfeiture?
- Not specified in the prompt.
Did any court decision trigger FDA approval under a noninfringement/invalidity basis?
- Not specified in the prompt.
How strong was Pfizer’s patent estate based on what was litigated in 1:19-cv-00615?
Answer (from provided information): Not specified in the prompt.
How many asserted patents were in play, and what claim scopes were at issue?
- Not specified in the prompt.
Were method-of-use, formulation, or process patents asserted versus composition-of-matter?
- Not specified in the prompt.
What Paragraph IV outcomes matter most for generic entry risk in this dispute?
Answer (from provided information): Not specified in the prompt.
Was there a finding of invalidity that removed the statutory bar?
- Not specified in the prompt.
Did infringement determinations limit the launch design-around options?
- Not specified in the prompt.
What settlement terms or business agreements resolved Par v. Pfizer 1:19-cv-00615?
Answer (from provided information): Not specified in the prompt.
Was there a license, covenant not to sue, or stipulated dismissal tied to a market-date?
- Not specified in the prompt.
Did any settlement include pediatric exclusivity, label changes, or manufacturing constraints?
- Not specified in the prompt.
Which companies were positioned as co-defendants or involved as stakeholders (other generics, distributors, or test firms)?
Answer (from provided information): Not specified in the prompt.
Were any parties added via amended pleadings or joinder?
- Not specified in the prompt.
How does this case compare to other Par v. Pfizer Hatch-Waxman disputes (risk and outcomes)?
Answer (from provided information): Not specified in the prompt.
Pattern recognition across Par’s portfolio of litigations with Pfizer
- Not specified in the prompt.
Key Case Facts (table)
| Field |
Value |
| Case name |
Par Pharmaceutical Inc v. Pfizer Inc |
| Case number |
1:19-cv-00615 |
| Court |
Not specified in the prompt |
| Filing date |
Not specified in the prompt |
| Asserted patents / Orange Book entries |
Not specified in the prompt |
| Status/decision type |
Not specified in the prompt |
| Settlement terms |
Not specified in the prompt |
| Generic launch implications |
Not specified in the prompt |
Key Takeaways
- A litigation summary with patent-by-patent claim results, court holdings, and launch/timing implications cannot be completed from the provided prompt.
- A complete actionable analysis requires the docket disposition and the asserted patent list to identify infringement/invalidity outcomes and any settlement-based launch constraints.
FAQs
- What is the docket disposition date for Par Pharmaceutical Inc v. Pfizer Inc, 1:19-cv-00615?
- Which specific Orange Book patents were listed against Pfizer’s product and challenged by Par?
- Did the case include claim construction (Markman), and what were the construed terms?
- Did the matter end in a final merits judgment, consent judgment, or a settlement dismissal?
- What is the FDA approval and exclusivity timeline impact if the litigation involved a stay of approval?
References
- Not available from the provided prompt.
